Clinical Trials Logo

Clinical Trial Summary

Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.


Clinical Trial Description

The purpose of this study is to assess treatment patterns and generate evidence on the effectiveness and safety of loncastuximab tesirine treatment in real-world practice. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05160064
Study type Observational [Patient Registry]
Source ADC Therapeutics S.A.
Contact
Status Withdrawn
Phase
Start date June 30, 2022
Completion date January 2025

See also
  Status Clinical Trial Phase
Completed NCT02891590 - Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas Phase 1
Completed NCT01068392 - Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) Phase 2
Terminated NCT01744912 - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Phase 1
Completed NCT03218072 - A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas Phase 1
Completed NCT01478269 - Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen N/A
Recruiting NCT02247609 - Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas Phase 1/Phase 2
Recruiting NCT00801216 - High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement Phase 2
Completed NCT01613300 - Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients Phase 2
Active, not recruiting NCT05773040 - A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas Phase 1